Saad Usmani, MD, Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center, discusses updated results from the phase 2 RedirecTT-1 study of telquetamab + teclistamab in patients with multiple myeloma (MM).
MM is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. When present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. Other features of the condition may include multiple infections, abnormal bleeding, bone pain, weak and/or easily broken bones, and numbness and/or weakness of the arms and legs. The exact underlying cause of MM is currently unknown.
RedirecTT-1 (NCT04586426) was a phase 1b/2 dose escalation and expansion study of talquetamab + teclistamab (NCT04586426) combination therapy in participants with relapsed/refractory MM. Talquetamab and teclistamab are first-in-class bispecific antibodies approved as monotherapies for triple-class exposed relapsed/refractory MM.
Recently, results on the safety and efficacy of Tal + Tec in patients with relapsed/refractory MM and extramedullary disease were presented at the 2025 American Society of Hematology (ASH) Annual Meeting. The data included updated results from the phase 2 RedirecTT-1 clinical trial with extended follow-up.
As of July 2025, 90 patients received Tal + Tec, with a median follow-up of 16.3 months. Overall response rate was 77.8% and 50% had a greater than or equal to complete response. Median duration of response was not estimable, 12-month progression free survival was 55.6%, and median overall survival was not estimable. Overall response rate was 90.7% in patients with EMD tumor volume less than25 cm2, 66.7% for 25–50 cm2 , and 65.4% for greater than 50 cm2.
Common adverse events included cytokine release syndrome and neutropenia. Taste changes, non-rash skin adverse events, and nail adverse events were all grade 1/2, and rash adverse events were mostly grade 1/2. ICANS occurred in 11 patients. Infections occurred in 72 patients, most commonly upper respiratory tract infection. Ten patients discontinued Tal + Tec due to treatment-emergent adverse events. Two patients discontinued Tal only due to adverse events. In total, 11 patients had grade 5 adverse events, 6 of which were deemed to be drug related by investigators.
For more information, click here.
To learn more about MM and other rare hematologic conditions, visit https://checkrare.com/diseases/hematologic-disorders/